Skip to main content

CAncer Risk and INsulin analoGues

Objective

Several studies have linked the use of insulins to the risk of cancer, and it is certainly plausible that as a growth factor, exposure to administered insulin could stimulate neoplastic growth. However, the meta-analyses of randomized clinical trials comparing different insulin analogues were too small to quantify the risks, especially the proportion of patients that were followed for more than 6 months. Hence, the European Medicines Agency has requested urgent research to determine the risks of cancer for users of insulin and insulin analogues, and investigate possible mechanisms of cancer promotion.
CARING will obtain precise data on the incidence of cancer in diabetic patients and determine any link with use of various insulin and insulin analogues. The study will utilise high quality prescription databases and other national datasources, integrated at European level with advanced methods of harmonising data. The study will take into account potential confounders. The project aims to determine the influence of drug dose on risk, and through a risk model, identify predictors of cancer for insulin users. A review of published evidence combined with a study of tumour characteristics and gene expression in breast cancer tumour collections will aid understanding of potential mechanisms of cancer initiation and/or promotion by insulin.
The project consortium involves some of the most experienced pharmacoepidemiology groups in Europe, and a leading cancer research institute. The consortium will liaise closely with the European Medicines Agency and other stakeholders throughout the study.

Field of science

  • /medical and health sciences/clinical medicine/cancer/breast cancer

Call for proposal

FP7-HEALTH-2011-single-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITEIT UTRECHT
Address
Heidelberglaan 8
3584 CS Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 926 269,75
Administrative Contact
M.L. De Bruin (Dr.)

Participants (6)

AARHUS UNIVERSITETSHOSPITAL
Denmark
EU contribution
€ 432 208
Address
Palle Juul-jensens Boulevard 99
8200 Aarhus
Activity type
Research Organisations
Administrative Contact
Peter Vestergaard (Dr.)
FOLKEHELSEINSTITUTTET
Norway
EU contribution
€ 329 396
Address
Lovisenberggata 8
0456 Oslo
Activity type
Research Organisations
Administrative Contact
Aage Tverdal (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 434 360
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Ms.)
TAMPEREEN YLIOPISTO
Finland
EU contribution
€ 130 040
Address
Kalevantie 4
33014 Tampere
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Susanna Airila (Ms.)
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 264 400
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sanna Leppämäki (Ms.)
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 457 500
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
Administrative Contact
Henri Van Luenen (Dr.)